trial · primary record
Pegylated interferon alpha2a
Myelofibrosis
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 18 |
| Primary completion | 2028-03 |
| Primary endpoint | Rate of dose-limiting toxicities (DLTs) during the DLT evaluation period |
| Registry ID | NCT05535764 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:39.030Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05535764
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.